FINRA on KaloBios Pharma (KBIO) 'we are not able to comment on open matters'
Tweet
Share
E-mail
Get Alerts KBIO Hot Sheet
Join SI Premium – FREE
In its response to StreetInsider.com related to trading action in KaloBios Pharma (NASDAQ: KBIO), FINRA said "we are not able to comment on open matters."
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- IMAC Holdings (BACK) halted on volatility, up 38%
- Capital One Financial (COF) call put ratio 1 call to 4.8 puts into quarter results and outlook
Create E-mail Alert Related Categories
Momentum Movers, Short Sales, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
